## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 20

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed purcuant to Section 16(a) of the Securities Evolution Act of 1024

msuuc	1011 <b>1</b> (b).			FIII							mpany Act			34			1-			
		Reporting Person*	<u>lical</u>				r Name <b>a</b> ia <b>The</b> :				Symbol NTLA						p of Reportin	ng Per	. ,	
Researc	<u>ch, Inc.</u>													_			er (give title	Δ	_	(specify
(Last) 250 MAS	(Fii	rst) (ETTS AVENUE	Middle)				of Earlies 2017	t Trans	action (f	Month	/Day/Year)					belov	v) ``		below)	
(Street) CAMBR (City)	IDGE M.	Α (	)2139 Zip)		4. If <i>i</i>	Ame	endment,	Date o	f Origina	al File	d (Month/Da	ay/Ye	ar)		i. Indiv ine) X	Forn	r Joint/Group n filed by Ond n filed by Mod on	e Rep	orting Pers	on
		Tabl	e I - No	n-Deriv	/ative	Se	curitie	s Acc	quired	, Dis	posed o	f, o	Ben	efici	ally (	Owne	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				)   E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					(A) or 3, 4 an	4 and 5) Secu Bend Own		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Price	•		ted action(s) 3 and 4)			(Instr. 4)
Common	Stock			12/12	/2017				S		1,523,00	00	D	\$18	.3(1)	4,1	129,903		<b>D</b> <sup>(2)</sup>	
		Та									osed of, onvertib					vned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution E (Month/Day/Year) if any (Month/Day/Year)		n Date,	Date, Transacti Code (Ins		tion of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)				9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forn Direc or In (I) (Ir	LO. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nu of	nount mber ares						
		Reporting Person* es for BioMed	dical R	esearc]	h, Inc.	•														
(Last)		(First)	(Mid	ldle)																

1. Name and Address  Novartis Instit		cal Research, Inc.
(Last)	(First)	(Middle)
250 MASSACHU	JSETTS AVENUE	
(Street)		
CAMBRIDGE	MA	02139
(City)	(State)	(Zip)
1. Name and Address NOVARTIS A	of Reporting Person <sup>*</sup>	
		(Middle)
NOVARTIS A	G (First)	(Middle)
NOVARTIS A (Last)	G (First)	(Middle)
NOVARTIS A  (Last)  LICHTSTRASSE	G (First)	(Middle)  CH 4056

## Explanation of Responses:

- $1. \ The \ price \ reported \ in \ Column \ 4 \ is \ exclusive \ of \ any \ fees, \ commissions \ or \ other \ expenses.$
- 2. The shares are held directly by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG.

**Novartis Institutes for** Biomedical Research, Inc. By: 12/14/2017 /s/Scott A. Brown, General Counsel

Novartis AG By: /s/ Christian 12/14/2017

Rehm, Authorized Signatory

Novartis AG By: /s/ Katja Roth
Pellanda, Authorized Signatory

12/14/

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.